What does PHARMA MANAGEMENT do?

PHARMA MANAGEMENT is a pharmacy in Landen. Public Limited, started on 13 January 1994, 1 establishment.

What is the address of PHARMA MANAGEMENT?

The registered office of PHARMA MANAGEMENT is located at Hannuitsesteenweg 78, 3400 Landen.

Is PHARMA MANAGEMENT still active?

Yes. According to the CBE (29 October 2026) PHARMA MANAGEMENT is active, legal situation “Normale toestand”, started on 13 January 1994.

Is PHARMA MANAGEMENT registered on Peppol?

Yes, PHARMA MANAGEMENT is registered on the Peppol network with ID 0208:0451878656.

What is the enterprise number of PHARMA MANAGEMENT?

The enterprise number of PHARMA MANAGEMENT is BE0451878656.

When was PHARMA MANAGEMENT founded?

PHARMA MANAGEMENT was founded on 13 January 1994.

Who are the directors of PHARMA MANAGEMENT?

According to the 2025 annual accounts, the directors of PHARMA MANAGEMENT are: Bart Hendrickx, Pascale Goethuys.

Is PHARMA MANAGEMENT a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 13 January 1994; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did PHARMA MANAGEMENT make in 2025?

PHARMA MANAGEMENT posted a profit after taxes of € 376,772 in financial year 2025.

What is the revenue of PHARMA MANAGEMENT?

As a small company, PHARMA MANAGEMENT is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 183,207.

How much does an employee at PHARMA MANAGEMENT earn?

The average wage cost per full-time employee at PHARMA MANAGEMENT was € 45,100 in 2025: staff costs of € 112,808 for 2.5 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does PHARMA MANAGEMENT have?

According to the 2025 annual accounts, PHARMA MANAGEMENT has 2.5 full-time equivalents (FTE).

Does PHARMA MANAGEMENT have a website?

Yes, PHARMA MANAGEMENT has a website at apotheek-hendrickxbart.be.

PHARMA MANAGEMENT (Public Limited) - Landen

Dossier PHARMA MANAGEMENT, printed on 29 October 2026 from databakkes.be/en/0451878656/pharma-management. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 10 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

PHARMA MANAGEMENT from Landen, company number BE0451878656, closed financial year 2025 with a result of € 376,772 after tax. For that financial year PHARMA MANAGEMENT recorded a gross margin of € 183,207 and equity of € 1.2 million. Compared with financial year 2024, the result moved from € 193,829 to € 376,772. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 29, 2026.

What it is worth Healthy

€ 1.2 million

▼ 31% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 376,772

▲ 94% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 36,135

▼ 47% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 910,993 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents

2.5

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 112,808

▲ 40% vs 2024

€ 45,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 37,637

▼ 34% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 5 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 347,019

▼ 75% vs 2024

€ 63,537 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.

Owed to suppliers

€ 1,938

▼ 15% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 24,011

▼ 60% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 513,792 Gross margin 2022: € 513,792 First fiscal year in the series	€ 526,485 Gross margin 2023: € 526,485 ▲ 2% vs 2022 (€ 513,792) Favourable step	€ 407,008 Gross margin 2024: € 407,008 ▼ 23% vs 2023 (€ 526,485) Unfavourable step	€ 183,207 Gross margin 2025: € 183,207 ▼ 55% vs 2024 (€ 407,008) Unfavourable step	▼ 55%
Profit after taxes	€ 227,344 Profit after taxes 2022: € 227,344 First fiscal year in the series	€ 212,730 Profit after taxes 2023: € 212,730 ▼ 6% vs 2022 (€ 227,344) Unfavourable step	€ 193,829 Profit after taxes 2024: € 193,829 ▼ 9% vs 2023 (€ 212,730) Unfavourable step	€ 376,772 Profit after taxes 2025: € 376,772 ▲ 94% vs 2024 (€ 193,829) Favourable step	▲ 94%
Equity	€ 2,405,701 Equity 2022: € 2,405,701 First fiscal year in the series	€ 1,518,400 Equity 2023: € 1,518,400 ▼ 37% vs 2022 (€ 2,405,701) Unfavourable step	€ 1,712,229 Equity 2024: € 1,712,229 ▲ 13% vs 2023 (€ 1,518,400) Favourable step	€ 1,178,008 Equity 2025: € 1,178,008 ▼ 31% vs 2024 (€ 1,712,229) Unfavourable step	▼ 31%
Total debts	€ 1,869,550 Total debts 2022: € 1,869,550 First fiscal year in the series	€ 1,969,669 Total debts 2023: € 1,969,669 ▲ 5% vs 2022 (€ 1,869,550) Unfavourable step	€ 1,824,590 Total debts 2024: € 1,824,590 ▼ 7% vs 2023 (€ 1,969,669) Favourable step	€ 1,998,881 Total debts 2025: € 1,998,881 ▲ 10% vs 2024 (€ 1,824,590) Unfavourable step	▲ 10%
Cash	€ 55,927 Cash 2022: € 55,927 First fiscal year in the series	€ 43,713 Cash 2023: € 43,713 ▼ 22% vs 2022 (€ 55,927) Unfavourable step	€ 68,666 Cash 2024: € 68,666 ▲ 57% vs 2023 (€ 43,713) Favourable step	€ 36,135 Cash 2025: € 36,135 ▼ 47% vs 2024 (€ 68,666) Unfavourable step	▼ 47%
Land & buildings	€ 406,398 Land & buildings 2022: € 406,398 First fiscal year in the series	€ 389,869 Land & buildings 2023: € 389,869 ▼ 4% vs 2022 (€ 406,398) Unchanged	€ 373,341 Land & buildings 2024: € 373,341 ▼ 4% vs 2023 (€ 389,869) Unchanged	€ 356,812 Land & buildings 2025: € 356,812 ▼ 4% vs 2024 (€ 373,341) Unchanged	▼ 4%
Retained profit	€ 1,380,701 Retained profit 2022: € 1,380,701 First fiscal year in the series	€ 1,456,400 Retained profit 2023: € 1,456,400 ▲ 5% vs 2022 (€ 1,380,701) Favourable step	€ 1,650,229 Retained profit 2024: € 1,650,229 ▲ 13% vs 2023 (€ 1,456,400) Favourable step	€ 1,116,008 Retained profit 2025: € 1,116,008 ▼ 32% vs 2024 (€ 1,650,229) Unfavourable step	▼ 32%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 137,031 Dividend 2023: € 137,031 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 ▼ 100% vs 2023 (€ 137,031) Unchanged	€ 910,993 Dividend 2025: € 910,993 Unchanged (€ 0) Unchanged
Bank debt	€ 1,497,004 Bank debt 2022: € 1,497,004 First fiscal year in the series	€ 1,436,265 Bank debt 2023: € 1,436,265 ▼ 4% vs 2022 (€ 1,497,004) Favourable step	€ 1,374,608 Bank debt 2024: € 1,374,608 ▼ 4% vs 2023 (€ 1,436,265) Favourable step	€ 347,019 Bank debt 2025: € 347,019 ▼ 75% vs 2024 (€ 1,374,608) Favourable step	▼ 75%
Balance sheet total	€ 4,275,251 Balance sheet total 2022: € 4,275,251 First fiscal year in the series	€ 3,488,069 Balance sheet total 2023: € 3,488,069 ▼ 18% vs 2022 (€ 4,275,251) Unchanged	€ 3,536,819 Balance sheet total 2024: € 3,536,819 ▲ 1% vs 2023 (€ 3,488,069) Unchanged	€ 3,176,889 Balance sheet total 2025: € 3,176,889 ▼ 10% vs 2024 (€ 3,536,819) Unchanged	▼ 10%
Employees (FTE)	2.3 Employees (FTE) 2022: 2.3 First fiscal year in the series	2.3 Employees (FTE) 2023: 2.3 Unchanged (2.3) Unchanged	2.5 Employees (FTE) 2024: 2.5 ▲ 0.2 vs 2023 (2.3) Unchanged	2.5 Employees (FTE) 2025: 2.5 Unchanged (2.5) Unchanged

Key figures of PHARMA MANAGEMENT, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARMA MANAGEMENT?

What happened at PHARMA MANAGEMENT in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 29, 2026 New annual accounts for financial year 2025: profit of € 376,772 (▲ 94% vs 2024). Source: NBB ↗
2019 Bart Hendrickx became a director. NBB
2019 Pascale Goethuys became a director. NBB
Feb 15, 1994 New establishment in Landen. KBO
Jan 13, 1994 Start of the company according to the CBE. KBO

In short

From € 227,344 profit in 2022 to € 376,772 profit in 2025.

Paid € 332,202 in corporate taxes since 2022.

Best year ever: 2025, with € 376,772 profit.

On average € 73,300 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Bart Hendrickx

Pascale Goethuys

PHARMA MANAGEMENT

Apotheek Bart Hendrickx 100%

Apotheek Attenhoven 100%

Behind PHARMA MANAGEMENT are Bart Hendrickx and Pascale Goethuys. It owns 100% of Apotheek Bart Hendrickx and 100% of Apotheek Attenhoven itself.

Directors

According to the 2025 annual accounts

Bart Hendrickx

Managing director

Also active at: APOTHEEK ATTENHOVEN, APOTHEEK BART HENDRICKX

since 2019

Pascale Goethuys

Director

since 2019

Establishments

Establishment units

Physical locations of this company

Registered office

Hannuitsesteenweg 78

3400 Landen

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

APOTHEEK BART HENDRICKX same network

€ 422,485 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS apotheek-hendrickxbart.be

Technologies

ASP.NETGoogle AnalyticsGoogle FontsIISSlickjQueryjQuery UI

Certifications & Partners

FEB/VBO

Hosting & Email

Email provider

Self-hosted

Hosting

LEASEWEB-NL-AMS-01 Netherlands, NL

Website info

HTTPS Ja

Features

Blog Newsletter Client portal Contact page

Security

✓ HTTPS

✓ SPF

✗ DMARC

Details

Company number

0451.878.656

VAT number

BE 0451.878.656

Registered office

Hannuitsesteenweg 78, 3400 Landen

Names & denominations

PHARMA MANAGEMENT

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

13 January 1994

Peppol

Active · Active since 8 Dec 2025

Contact

apotheek-hendrickxbart.be

Activities · NACE

Detailhandel in farmaceutische producten

Overige rechtskundige dienstverlening

Advocatenkantoor en juridische adviseurs

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARMA MANAGEMENT

Warning lights

Financials

What happened to PHARMA MANAGEMENT?

Management

Directors

Establishments

Establishment units

Who else lives here?

Website

Technologies

Certifications & Partners

Hosting & Email

Website info

Features

Security

Details

Frequently asked questions